Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Nasopharyngeal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 154 active trials
1 drug · 6 active trials
1 drug · 21 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Phase 2 | Phase 2 | 7 | 2 | 0 | 15 | 0 | — | — | Oct 8, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 3 | 0 | 0 | 5 | 0 | — | — | Jan 30, 2017 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | May 27, 2026 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2008-01 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2015-02 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 11, 2022 |
| Vorinostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Mar 3, 2006 |
| Interferon Beta-1a | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 10, 2023 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2022-06 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 25, 2024 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-12 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2020 |
| Icotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-02 |
| Paclitaxel Liposome | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 14, 2016 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 7, 2017 |
| Aspirin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2018 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2017-01 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-02 |
| Doxorubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 15, 2004 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-06 |
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2018 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-08 |
| Temoporfin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-01 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Tranilast | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2022 |
| Zoledronic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-09 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.